Pre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Baidu (BIDU) PT Raised to $200 at Susquehanna
March 3, 2022 6:30 AM ESTSusquehanna analyst Shyam Patel raised the price target on Baidu (NASDAQ: BIDU) to $200.00 (from $175.00) while maintaining a Positive rating following solid Q4 given the macro backdrop.
The analyst commented, "Although BIDU continues to be cautious around the pandemic and macro situation in... More
Target (TGT) PT Lowered to $252 at Jefferies
March 2, 2022 7:58 AM ESTJefferies analyst Stephanie Wissink lowered the price target on Target (NYSE: TGT) to $252.00 (from $260.00) while maintaining a Hold rating following results.
The analyst commented, "Q4 comps were light at +9% driven fully by traffic but margins were better, leading to Q4 EPS beat.... More
Target (TGT) PT Raised to $290 at JPMorgan, 'More Upside Expected in Near Term'
March 1, 2022 5:33 PM ESTJPMorgan analyst Christopher Horvers raised the price target on Target (NYSE: TGT) to $290.00 (from $262.00) while maintaining a Overweight rating.
The analyst comments "TGT is a core long-term holding given its ability to compete in the new world of omni-channel retailing and its... More
CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
March 1, 2022 10:13 AM ESTBrookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $12.00 (from $7.20) while maintaining a Buy rating following FDA approval for Pacritinib (Vonjo) in Myelofibrosis.
The analyst commented, "The timing of this FDA-approval is as expected and the prescribing label, with no black box warning and an... More
